AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30864473 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol compliance
Number of subjects: 100
Study 30864473 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib compliance
Number of subjects: 100
Study 30864473 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone immediate release (IR) compliance
Number of subjects: 100
Study 30864473 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone IR quantity compliance
Number of subjects: 100
Study 28236467 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy screening
Number of subjects: 170034
Study 28236467 — intervention group
Group type: COMPARATOR
Intervention: Control group (not contacted)
Number of subjects: 170034
Study 25580979 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 81
Study 25580979 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Exercise (MICE)
Number of subjects: 81
Study 23972891 — intervention group
Group type: EXPERIMENTAL
Intervention: Cartridge-insertion technique
Number of subjects: 144
Study 23972891 — intervention group
Group type: COMPARATOR
Intervention: Wound-assisted technique
Number of subjects: 144
Study 21653795 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed formula
Number of subjects: 2159
Study 21653795 — intervention group
Group type: COMPARATOR
Intervention: Standard cow milk-based weaning formulas
Number of subjects: 2159
Study 19661695 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium- and long-chain triacylglycerols (MLCT) oil
Number of subjects: 2
Study 19661695 — intervention group
Group type: COMPARATOR
Intervention: Long-chain triacylglycerols (LCT) oil
Number of subjects: 2
Study 17381566 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5% (20 ml)
Number of subjects: 120
Study 17381566 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9%
Number of subjects: 120
Study 14688594 — intervention group
Group type: COMPARATOR
Intervention: Captopril renography
Number of subjects: 29
Study 14688594 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise renography
Number of subjects: 29
Study 14688594 — intervention group
Group type: COMPARATOR
Intervention: Captopril renography (patient basis)
Number of subjects: 29
Study 14688594 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise renography (patient basis)
Number of subjects: 29
Study 12363117 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (median dose 150 mg, range 50-300 mg)
Number of subjects: 42
Study 12363117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 12363117 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 42
Study 9768652 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) therapy
Number of subjects: 15
Study 7979646 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (40 mg/kg)
Number of subjects: 0
Study 7979646 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg)
Number of subjects: 0
Study 2589761 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype endotracheal tube (ETT)
Number of subjects: 0
Study 2589761 — intervention group
Group type: COMPARATOR
Intervention: Standard endotracheal tube (ETT)
Number of subjects: 0
Study 1103574 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline (Ludiomil)
Number of subjects: 67
Study 1103574 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (Elavil)
Number of subjects: 67
Study 1103574 — intervention group
Group type: COMPARATOR
Intervention: Maprotiline and Amitriptyline (both drugs)
Number of subjects: 67
Study 30729363 — intervention group
Group type: EXPERIMENTAL
Intervention: Full Program condition (access to all services available from the Relief Nursery)
Number of subjects: 0
Study 30729363 — intervention group
Group type: COMPARATOR
Intervention: Respite Care condition (access only to respite care and referrals to services provided by other community agencies)
Number of subjects: 0
Study 30811280 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg plus ipilimumab 1 mg/kg (NIVO3+IPI1)
Number of subjects: 360
Study 30811280 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg (NIVO1+IPI3)
Number of subjects: 360
Study 27007714 — intervention group
Group type: EXPERIMENTAL
Intervention: Engage in Education‐London (EiE‐L) intervention, delivered over 12 weeks
Number of subjects: 644
Study 27007714 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 644
Study 25622639 — intervention group
Group type: EXPERIMENTAL
Intervention: MiQuit intervention (12-week tailored, supportive, interactive text message self-help cessation support)
Number of subjects: 400
Study 25622639 — intervention group
Group type: COMPARATOR
Intervention: NHS leaflet aimed at helping them to stop smoking
Number of subjects: 400
Study 23695652 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal medical therapy (OMT) including lifestyle intervention and intensive secondary prevention with proven pharmacotherapies
Number of subjects: 0
Study 23695652 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial revascularization
Number of subjects: 0
Study 23695652 — intervention group
Group type: EXPERIMENTAL
Intervention: COURAGE and FAME 2 trials
Number of subjects: 0
Study 21105835 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 96
Study 21105835 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptive pills (OCPs)
Number of subjects: 96
Study 19478339 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO+ProH beverage (6% carbohydrate + 1.8% protein hydrolysate)
Number of subjects: 13
Study 19478339 — intervention group
Group type: COMPARATOR
Intervention: CHO beverage (6% carbohydrate)
Number of subjects: 13
Study 16636139 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantile regression model with random effects using asymmetric Laplace distribution
Number of subjects: 0
Study 16636139 — intervention group
Group type: COMPARATOR
Intervention: Mean regression with random effects
Number of subjects: 0
Study 14583439 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol 2 (6 h of mild hyperglycemia, approximately 7 mmol/l)
Number of subjects: 25
Study 14583439 — intervention group
Group type: COMPARATOR
Intervention: Protocol 3 (6 h of euglycemia)
Number of subjects: 25
Study 14583439 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol 1 (glucose varied to mimic a postprandial pattern, peak glucose approximately 11.1 mmol/l)
Number of subjects: 25
Study 11804426 — intervention group
Group type: EXPERIMENTAL
Intervention: P1 medium supplemented with 20% SSS (Group 3)
Number of subjects: 956
Study 11804426 — intervention group
Group type: COMPARATOR
Intervention: P1 medium supplemented with 10% SSS (Group 2)
Number of subjects: 956
Study 11804426 — intervention group
Group type: COMPARATOR
Intervention: IVF medium (Group 1)
Number of subjects: 956
Study 9415507 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician pain scale (assessed by visual analogue scale)
Number of subjects: 91
Study 9415507 — intervention group
Group type: COMPARATOR
Intervention: No analgesic treatment
Number of subjects: 91
Study 8395380 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMW heparin) administered subcutaneously once daily
Number of subjects: 241
Study 8395380 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 241
Study 3706840 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia with sodium thiopentone, fentanyl, enflurane, and vecuronium
Number of subjects: 70
Study 3706840 — intervention group
Group type: COMPARATOR
Intervention: Spinal anaesthesia with 3 ml 0.5% bupivacaine in isobaric solution
Number of subjects: 70
Study 31846067 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomosis (IA)
Number of subjects: 140
Study 30307692 — intervention group
Group type: EXPERIMENTAL
Intervention: Buzzy
Number of subjects: 60
Study 30307692 — intervention group
Group type: EXPERIMENTAL
Intervention: ShotBlocker
Number of subjects: 60
Study 30307692 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 30307692 — intervention group
Group type: EXPERIMENTAL
Intervention: Buzzy and ShotBlocker
Number of subjects: 60
Study 26846664 — intervention group
Group type: EXPERIMENTAL
Intervention: Videos of chewing people
Number of subjects: 0
Study 26846664 — intervention group
Group type: COMPARATOR
Intervention: Videos of nature and buildings (Control)
Number of subjects: 0
Study 25153050 — intervention group
Group type: EXPERIMENTAL
Intervention: Kiosk
Number of subjects: 317
Study 25153050 — intervention group
Group type: COMPARATOR
Intervention: IPS
Number of subjects: 317
Study 21919060 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0
Study 21919060 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 0
Study 21919060 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline responders
Number of subjects: 0
Study 21919060 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline responders
Number of subjects: 0
Study 21919060 — intervention group
Group type: COMPARATOR
Intervention: Sertraline non-responders
Number of subjects: 0
Study 21919060 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline non-responders
Number of subjects: 0
Study 20206786 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER (3, 9, and 15 mg/d; 6, 9, and 12 mg/d; 6 and 12 mg/d)
Number of subjects: 1306
Study 20206786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1306
Study 17012146 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic hypoxia (IH) at an end‐tidal partial pressure of O(2) of 55 mmHg
Number of subjects: 10
Study 17012146 — intervention group
Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 10
Study 16266859 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg n-3 PUFA + 700 mg canola oil
Number of subjects: 21
Study 16266859 — intervention group
Group type: COMPARATOR
Intervention: 1 g canola oil (control)
Number of subjects: 21
Study 12019663 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20-40 mg daily)
Number of subjects: 242
Study 12019663 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20-60 mg daily)
Number of subjects: 242
Study 10466664 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide oral azithromycin treatment (three doses with intervals of 1 week)
Number of subjects: 1511
Study 10466664 — intervention group
Group type: COMPARATOR
Intervention: 1% topical tetracycline (once daily for 6 weeks)
Number of subjects: 1511
Study 7604667 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori positive patients
Number of subjects: 200
Study 7604667 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori status
Number of subjects: 200
Study 7604667 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonization rate
Number of subjects: 200
Study 7604667 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication rate
Number of subjects: 200
Study 7604667 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic gastritis
Number of subjects: 200
Study 7604667 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial endoscopy results
Number of subjects: 200
Study 1731005 — intervention group
Group type: EXPERIMENTAL
Intervention: High PEEP (12 to 14 cm H2O)
Number of subjects: 74
Study 1731005 — intervention group
Group type: COMPARATOR
Intervention: Low PEEP (3 to 5 cm H2O)
Number of subjects: 74
Study 3918426 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary thrombolytic therapy with streptokinase (STK)
Number of subjects: 64
Study 3918426 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids and intracoronary and intravenous nitroglycerin (NTG group)
Number of subjects: 64
Study 3918426 — intervention group
Group type: COMPARATOR
Intervention: Conventional means (control group)
Number of subjects: 64
Study 31710269 — intervention group
Group type: EXPERIMENTAL
Intervention: SBIRT mobile app
Number of subjects: 101
Study 31710269 — intervention group
Group type: COMPARATOR
Intervention: Control (no app)
Number of subjects: 101
Study 31554937 — intervention group
Group type: EXPERIMENTAL
Intervention: Esaxerenone monotherapy
Number of subjects: 368
Study 31554937 — intervention group
Group type: EXPERIMENTAL
Intervention: Esaxerenone with CCB
Number of subjects: 368
Study 31554937 — intervention group
Group type: EXPERIMENTAL
Intervention: Esaxerenone with RAS inhibitor
Number of subjects: 368
Study 31554937 — intervention group
Group type: EXPERIMENTAL
Intervention: Esaxerenone
Number of subjects: 368
Study 29797621 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco Status Project (TSP) Facebook intervention
Number of subjects: 500
Study 29797621 — intervention group
Group type: COMPARATOR
Intervention: Referral to the National Cancer Institute Smokefree.gov website (Control)
Number of subjects: 500
Study 25533646 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine, 800 mg, three times daily for 12 weeks
Number of subjects: 185
Study 25533646 — intervention group
Group type: COMPARATOR
Intervention: Placebo, three times daily for 12 weeks
Number of subjects: 185
Study 25697457 — intervention group
Group type: EXPERIMENTAL
Intervention: 532-nm subthreshold laser grid photocoagulation
Number of subjects: 23
Study 25697457 — intervention group
Group type: COMPARATOR
Intervention: Threshold laser grid photocoagulation
Number of subjects: 23
Study 23566712 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 130/0.4
Number of subjects: 200
Study 23566712 — intervention group
Group type: COMPARATOR
Intervention: Balanced electrolyte solution
Number of subjects: 200
Study 19853518 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 24
Study 19853518 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 24
Study 19114201 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose cefazolin (2 g)
Number of subjects: 838
Study 19114201 — intervention group
Group type: COMPARATOR
Intervention: 24-hour treatment of cefazolin (2-g initial dose, followed by 1 g every 8 hours)
Number of subjects: 838
Study 16669901 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive referral to 12-Step self-help groups
Number of subjects: 345
Study 16669901 — intervention group
Group type: COMPARATOR
Intervention: Standard referral
Number of subjects: 345
Study 12828083 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-a-day interferon-beta (3 MU) for 3 weeks followed by once-a-day interferon-beta (6 MU) for 5 weeks (group A)
Number of subjects: 49
Study 12828083 — intervention group
Group type: COMPARATOR
Intervention: Once-a-day interferon-beta (6 MU) for 8 weeks (group B)
Number of subjects: 49
Study 12828083 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-a-day interferon-beta (group A)
Number of subjects: 49
Study 12828083 — intervention group
Group type: COMPARATOR
Intervention: Once-a-day interferon-beta (group B)
Number of subjects: 49
Study 11074884 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I-lipiodol (1110-MBq dose) administered into the hepatic artery
Number of subjects: 28
Study 7700739 — intervention group
Group type: EXPERIMENTAL
Intervention: End-stage renal disease (ESRD)
Number of subjects: 35
Study 7700739 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterminal chronic renal failure
Number of subjects: 35
Study 7700739 — intervention group
Group type: COMPARATOR
Intervention: Control group (idiopathic short stature)
Number of subjects: 35
Study 2695130 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 381
Study 2695130 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 381
Study 79319 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-month initial intensive phase of streptomycin, isoniazid, rifampin, and pyrazinamide followed by daily thiacetazone and isoniazid
Number of subjects: 0
Study 79319 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month initial intensive phase of streptomycin, isoniazid, rifampin, and pyrazinamide followed by twice-weekly administration of streptomycin, isoniazid, and pyrazinamide
Number of subjects: 0
Study 79319 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen omitting pyrazinamide from the initial intensive 2-month phase
Number of subjects: 0
Study 79319 — intervention group
Group type: EXPERIMENTAL
Intervention: Total duration of chemotherapy increased from 6 months to 8 months
Number of subjects: 0
Study 30362982 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Games (VG)
Number of subjects: 180
Study 30362982 — intervention group
Group type: EXPERIMENTAL
Intervention: Cartoon Movies (CM)
Number of subjects: 180
Study 30362982 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental Interaction (PI)
Number of subjects: 180
Study 30362982 — intervention group
Group type: COMPARATOR
Intervention: Control group (no distraction)
Number of subjects: 180
Study 29097166 — intervention group
Group type: EXPERIMENTAL
Intervention: Active product (125 mL once-a-day drink containing Fortasyn Connect)
Number of subjects: 311
Study 29097166 — intervention group
Group type: COMPARATOR
Intervention: Control product
Number of subjects: 311
Study 29097166 — intervention group
Group type: EXPERIMENTAL
Intervention: Active product
Number of subjects: 311
Study 25399241 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly acupuncture treatment (n = 118)
Number of subjects: 240
Study 25399241 — intervention group
Group type: COMPARATOR
Intervention: Oral tolterodine tartrate 2 mg twice daily (n = 122)
Number of subjects: 240
Study 24073528 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillating-rotating (O-R) power toothbrush
Number of subjects: 462
Study 21680210 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral morphine 0.25 mg/kg body weight
Number of subjects: 50
Study 21680210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 18375792 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab treatment
Number of subjects: 0
Study 18375792 — intervention group
Group type: COMPARATOR
Intervention: Control individuals
Number of subjects: 0
Study 16935098 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (2 g as an intravenous bolus before sternotomy)
Number of subjects: 100
Study 16935098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 16935098 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (from meta-analysis)
Number of subjects: 100
Study 12903849 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening mammography
Number of subjects: 0
Study 10889591 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous IL‐2 (7.5 mIU twice per day in 5-day courses every 8 weeks) + ART
Number of subjects: 82
Study 10889591 — intervention group
Group type: COMPARATOR
Intervention: ART alone
Number of subjects: 82
Study 10889591 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous IL‐2 + ART
Number of subjects: 82
Study 9096917 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (30 mg/day) added to probucol treatment for 12 weeks
Number of subjects: 27
Study 9096917 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (30 mg/day)
Number of subjects: 27
Study 8420593 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous mCPP (0.1 mg/kg)
Number of subjects: 27
Study 8420593 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mCPP (0.5 mg/kg)
Number of subjects: 27
Study 8420593 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous mCPP
Number of subjects: 27
Study 8420593 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mCPP
Number of subjects: 27
Study 8420593 — intervention group
Group type: EXPERIMENTAL
Intervention: Metergoline pretreatment prior to intravenous mCPP
Number of subjects: 27
Study 8420593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 2868029 — intervention group
Group type: EXPERIMENTAL
Intervention: dipyridamole (Persantine) plus aspirin
Number of subjects: 3128
Study 2868029 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 3128
Study 30006262 — intervention group
Group type: EXPERIMENTAL
Intervention: GAF‐ID (internet-based behavioural activation with lay counsellor support)
Number of subjects: 313
Study 30006262 — intervention group
Group type: COMPARATOR
Intervention: Online psychoeducation without support
Number of subjects: 313
Study 27777668 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated QI curriculum
Number of subjects: 105
Study 27777668 — intervention group
Group type: COMPARATOR
Intervention: Control group (midpoint)
Number of subjects: 105
Study 27777668 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention group (midpoint)
Number of subjects: 105
Study 27777668 — intervention group
Group type: EXPERIMENTAL
Intervention: Late intervention group
Number of subjects: 105
Study 25415040 — intervention group
Group type: EXPERIMENTAL
Intervention: Support from the central research team
Number of subjects: 39
Study 25415040 — intervention group
Group type: EXPERIMENTAL
Intervention: Importance of the research question
Number of subjects: 39
Study 25415040 — intervention group
Group type: COMPARATOR
Intervention: Low child eligibility rates
Number of subjects: 39
Study 25415040 — intervention group
Group type: COMPARATOR
Intervention: Integration of trial processes within routine workloads
Number of subjects: 39
Study 22686966 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (21 mg)
Number of subjects: 99
Study 22686966 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 99
Study 19891665 — intervention group
Group type: EXPERIMENTAL
Intervention: CB-01-05 MMX 210 mg tablets
Number of subjects: 141
Study 19891665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 18384882 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 93
Study 18384882 — intervention group
Group type: COMPARATOR
Intervention: non‐SSRIs
Number of subjects: 93
Study 16427529 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (0.5 mg/kg bolus over 10 minutes, followed by continuous infusion at 1 mg/kg per hour)
Number of subjects: 56
Study 16427529 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with fentanyl (2.0 microg/kg per hour)
Number of subjects: 56
Study 16427529 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol alone
Number of subjects: 56
Study 16427529 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with fentanyl
Number of subjects: 56